Results 221 to 230 of about 201,064 (349)

Targeting Immunologic Pathways in Eosinophilic Granulomatosis With Polyangiitis: Translating Emerging Evidence Into Clinical Practice

Allergy, EarlyView.
ABSTRACT Eosinophilic granulomatosis with polyangiitis (EGPA) is a rare and potentially life‐threatening systemic, inflammatory disease with multi‐organ manifestations, variable presentation and complex pathology. Multiple interconnected immunological pathways are implicated in EGPA pathology, including a type‐2 immune response driving predominantly ...
Harold Wilson‐Morkeh, Lior Seluk, Philipp Bosch, Carolina Aguiar, Jens Thiel, Bernhard Hellmich, Michael E. Wechsler, Salman Siddiqui   +7 more
wiley   +1 more source

Antiseizure Treatments and Liver Injury: Expect (and Prevent) the Unexpected. [PDF]

Epilepsy Curr
Bunch M, Klocke S, Woodrich N, Barritt AS, Eyal S.   +4 more
europepmc   +1 more source

Update on Non‐Biological and RNA‐Based Therapeutics in Chronic Inflammatory Diseases: Precision Medicine Through Small Molecules: An EAACI Position Paper

Allergy, EarlyView.
ABSTRACT In the last decades, critical advancements in research technology and knowledge on disease mechanisms steered therapeutic approaches for chronic inflammatory diseases towards unprecedented target specificity. For allergic and chronic lung diseases, biologic drugs pioneered this goal, acquiring on the way—through the clinical use of monoclonal ...
F. Roth‐Walter, I. M. Adcock, C. Benito‐Villalvilla, R. Bianchini, L. Bjermer, G. Caramori, L. Cari, K. F. Chung, Z. Diamant, I. Eguiluz‐Gracia, E. F. Knol, M. Jesenak, F. Levi‐Schaffer, G. Nocentini, L. O'Mahony, O. Palomares, F. Redegeld, M. Sokolowska, B. Van Esch, M. Zurlo, C. Stellato   +20 more
wiley   +1 more source

Common Adverse Reactions and Management Strategies of First-Line Anti-Tuberculosis Drugs. [PDF]

Infect Drug Resist
He K, Zhang J, Du X, He X, Zeng Y, Liu M.   +5 more
europepmc   +1 more source

Idelalisib given front-line for treatment of chronic lymphocytic leukemia causes frequent immune-mediated hepatotoxicity.

Blood, 2016
B. Lampson, S. Kasar, T. R. Matos, E. Morgan, L. Rassenti, M. Davids, D. Fisher, A. Freedman, C. Jacobson, P. Armand, J. Abramson, J. Arnason, T. Kipps, J. Fein, S. Fernandes, John R. Hanna, J. Ritz, Haesook T. Kim, Jennifer R. Brown   +18 more
semanticscholar   +1 more source

Triptolide capsule enables proteinuria reduction and renal stabilization in advanced alport syndrome beyond standard therapy

Rheumatology &Autoimmunity, EarlyView.
Zhuo‐ran Song, Na Li, Yang Li, Hong Zhang, Xu‐jie Zhou   +4 more
wiley   +1 more source

Measuring Propidium Iodide Brightness as a Function of Viability: A High‐Throughput Quantitative Assessment of Hepatic Spheroids

Artificial Organs, EarlyView.
The graphical abstract illustrates our rapid PI‐based spheroid viability assay: hepatocyte spheroids are formed and stained with AO/PI, imaged after a 15‐min incubation, and analyzed for PI brightness normalized to area. This metric correlates strongly with functional urea/DNA output, validating PI intensity as a fast, reliable indicator of spheroid ...
Michael G. Megaly, Diane Tobolt, Bat‐Erdene Namsrai, Benjamin Fisher, Anthony An‐Fa Dahm Chen, Joseph Sushil Rao, Srivasupradha Ramesh, Anudari Chimedtseren, Mark Clemens, Charles Y. Lee, John C. Bischof, Erik B. Finger   +11 more
wiley   +1 more source

Mechanistic insights into triclosan-induced hepatotoxicity: A network toxicology and molecular docking approach. [PDF]

PLoS One
Liu F, Zhao Y, Zhu D, Wang J, Zhuang Z, Chen Y, Su Y, Tu Z.   +7 more
europepmc   +1 more source

Assessing Major Adverse Liver Outcomes With Baclofen Compared to Acamprosate in Compensated Alcohol‐Associated Cirrhosis

Alimentary Pharmacology &Therapeutics, EarlyView.
We conducted a nationwide, multicenter cohort study using a target trial emulation framework to compare baclofen and acamprosate in patients with compensated alcohol‐associated cirrhosis. After matching, baclofen initiation was associated with a higher 1‐year risk of major adverse liver outcomes, driven primarily by hepatic encephalopathy, particularly
Yee Hui Yeo, Sepideh Mehravar, Ellen Choi, Ju Dong Yang, Hyun‐Seok Kim, Yun Wang, Aarshi Vipani, Hirsh D. Trivedi, Walid Ayoub, Parnian Naji, Alexander Kuo, Chun‐Ying Wu, Lorenzo Leggio, Juan Pablo Arab   +13 more
wiley   +1 more source

Hepatotoxicity of new-generation ALK inhibitors versus crizotinib in patients with non-small cell lung cancer: A systematic review and meta-analysis. [PDF]

iScience
Luo X, Du X, Chen Q, Wang C, Li L, He X, Gong Y, Chen J, Zhong X, Liu Y, Zhang X, Huang L.   +11 more
europepmc   +1 more source